Table 2:
Clinical trials currently recruiting, exploring novel agents and combinations in PTLD
| Agents | PTLD Disease status | Study phase | Trial status | ClinicalTrials.gov Identifier |
|---|---|---|---|---|
| Brentuximab vedotin + Rituximab | Untreated CD30+ and/or EBV+ CD20+ | I/II | Active, not recruiting | NCT04138875 |
| Risk stratified sequential treatment with rituximab+ brentuximab vedotin +/− bendamustine (RBvB) | Untreated CD30+ /CD20+ | I/II | Not yet recruiting | |
| Risk-stratified sequential treatment with Rituximab SC +/− CHOP-21 or Rituximab SC + CHOP-21 alternating with DHAOx (The PTLD-2 Trial) | Untreated | II | Recruiting | NCT02042391 |
| Rituximab + Acalabrutinib | Untreated | II | Not yet recruiting | NCT04337827 |
| Tabelecleucel | rituximab refractory EBV+ | III | Recruiting | NCT03392142* NCT03394365/NCT02822495 |
| Tacrolimus-resi stant autologous EBV-specific cytotoxic T-cells | De novo or resistant to rituximab EBV+ | I | Recruiting | NCT03131934 |
| EBV-specific T-cell lines | EBV+ | I | Recruiting | NCT02580539 |
| Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes | CD30+ | I | Not yet recruiting | NCT04288726 |
| Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder (ANHL1522 COG) | Newly diagnosed and relapsed EBV+ pediatric | II | recruiting | NCT02900976 * |
| VRx-3996 + valganciclovir | Relapsed/refractory EBV+ | I/II | Recruiting | NCT03397706 |
*
Includes a pediatric population